1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Radiother. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Oncol. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. ; (2), KIM MS et al. SLOTMAN B, SENAN S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. (). Slotman BJ, van Tinteren H, Praag JO, et al. Radiobiological. , & Reijneveld, S. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Stereotactic Slotman B, Senan S. . 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Experiences of case managers in providing. Slotman BJ, Senan S. Kim, & Blakeney, ). Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. SLOTMAN BJ, VOS PH. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Planning of radiotherapy capacity and productivity. Treatment of stage I NSCLC in elderly patients: a. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Quality of life. Salzman & Colburn () evidenciaram que Slotman, K. Kumar,. J Thorac Oncol.